Stockreport

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III Epsolay® Program for the Treatment of Papulopustular Rosacea

Sol-Gel Technologies Ltd.  (SLGL) 
Last sol-gel technologies ltd. earnings: 11/13 07:05 am Check Earnings Report
PDF Patient enrollment of the pivotal Phase III Epsolay clinical trials is on schedule Top-line results expected in 2019 NESS ZIONA, Israel, Sept. 25, 2018 (GLOBE NEWSWI [Read more]